BioMark Diagnostics Inc.

BUX.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 30M. In comparison, TMO.NE has a market cap of 207.1B. Regarding current trading prices, BUX.CN is priced at CA$0.33, while TMO.NE trades at CA$14.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -16.50, whereas TMO.NE's P/E ratio is 23.09. In terms of profitability, BUX.CN's ROE is +2.24%, compared to TMO.NE's ROE of +0.13%. Regarding short-term risk, BUX.CN is more volatile compared to TMO.NE. This indicates potentially higher risk in terms of short-term price fluctuations for BUX.CN.

BUX.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 30M. In comparison, EDT.TO has a market cap of 239.5M. Regarding current trading prices, BUX.CN is priced at CA$0.33, while EDT.TO trades at CA$0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -16.50, whereas EDT.TO's P/E ratio is -10.50. In terms of profitability, BUX.CN's ROE is +2.24%, compared to EDT.TO's ROE of +0.79%. Regarding short-term risk, BUX.CN is less volatile compared to EDT.TO. This indicates potentially lower risk in terms of short-term price fluctuations for BUX.CN.

BUX.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 30M. In comparison, AKU.TO has a market cap of 45.2M. Regarding current trading prices, BUX.CN is priced at CA$0.33, while AKU.TO trades at CA$0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -16.50, whereas AKU.TO's P/E ratio is -0.14. In terms of profitability, BUX.CN's ROE is +2.24%, compared to AKU.TO's ROE of -5.50%. Regarding short-term risk, BUX.CN is less volatile compared to AKU.TO. This indicates potentially lower risk in terms of short-term price fluctuations for BUX.CN.

BUX.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 30M. In comparison, SONA.CN has a market cap of 42.3M. Regarding current trading prices, BUX.CN is priced at CA$0.33, while SONA.CN trades at CA$0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -16.50, whereas SONA.CN's P/E ratio is -13.00. In terms of profitability, BUX.CN's ROE is +2.24%, compared to SONA.CN's ROE of -2.51%. Regarding short-term risk, BUX.CN is less volatile compared to SONA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for BUX.CN.

BUX.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 30M. In comparison, IZO.CN has a market cap of 14.7M. Regarding current trading prices, BUX.CN is priced at CA$0.33, while IZO.CN trades at CA$0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -16.50, whereas IZO.CN's P/E ratio is -6.75. In terms of profitability, BUX.CN's ROE is +2.24%, compared to IZO.CN's ROE of +0.47%. Regarding short-term risk, BUX.CN is less volatile compared to IZO.CN. This indicates potentially lower risk in terms of short-term price fluctuations for BUX.CN.

BUX.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 30M. In comparison, SZLS.TO has a market cap of 4.9M. Regarding current trading prices, BUX.CN is priced at CA$0.33, while SZLS.TO trades at CA$0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -16.50, whereas SZLS.TO's P/E ratio is -0.25. In terms of profitability, BUX.CN's ROE is +2.24%, compared to SZLS.TO's ROE of +0.13%. Regarding short-term risk, BUX.CN is more volatile compared to SZLS.TO. This indicates potentially higher risk in terms of short-term price fluctuations for BUX.CN.

BUX.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 30M. In comparison, SCRN.CN has a market cap of 1.5M. Regarding current trading prices, BUX.CN is priced at CA$0.33, while SCRN.CN trades at CA$0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -16.50, whereas SCRN.CN's P/E ratio is -0.25. In terms of profitability, BUX.CN's ROE is +2.24%, compared to SCRN.CN's ROE of -14.30%. Regarding short-term risk, BUX.CN is more volatile compared to SCRN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for BUX.CN.

BUX.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BUX.CN stands at 30M. In comparison, MEDV.NE has a market cap of 810.6K. Regarding current trading prices, BUX.CN is priced at CA$0.33, while MEDV.NE trades at CA$0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BUX.CN currently has a P/E ratio of -16.50, whereas MEDV.NE's P/E ratio is -0.09. In terms of profitability, BUX.CN's ROE is +2.24%, compared to MEDV.NE's ROE of +0.48%. Regarding short-term risk, BUX.CN is less volatile compared to MEDV.NE. This indicates potentially lower risk in terms of short-term price fluctuations for BUX.CN.